Facebook Glitches Allow Banned US Election Advertisements to Recirculate

first_imgRival parties complained new advertisments had been appearing despite the policy.“We’re investigating the issues of some ads being paused incorrectly, and some advertisers having trouble making changes to their campaigns,” Facebook product manager Rob Leathern said in a tweeted message when the ban kicked in on Tuesday.“We’re working quickly on these fixes.”California-based Facebook has tightened its rules on political advertising ahead of the 2020 election. In particular, it has prohibited attempts to undermine the electoral process.Are iPhone 12 mini, HomePod mini the Perfect Apple Devices for India? We discussed this on Orbital, our weekly technology podcast, which you can subscribe to via Apple Podcasts, Google Podcasts, or RSS, download the episode, or just hit the play button below. Facebook on Monday acknowledged glitches in enforcing its policy on removing misleading political advertising for the US election after a report revealed banned messages were being recirculated.The social media giant, which has faced intense scrutiny over its handling of political misinformation, said it took action after a media report showing loopholes allowing activist groups to repost advertisements that had been banned after third-party fact checks.- Advertisement – The Wall Street Journal report said some ads supporting President Donald Trump and containing false claims about Democrat Joe Biden had been reposted and shared by a conservative group after the original messages were blocked.Facebook began removing the reposted ads after the Journal report over the weekend.“When a fact-checker applies a rating, we apply a label and demote it while also rejecting it as an ad, this is true for all ratings,” a Facebook spokesperson told AFP.- Advertisement – “We reviewed these ads and are taking action on those that violate our policies, while also working to improve how we find similar ads to those that were already rated.”The Journal said the advertisements were being run by the American Principles Project, a conservative group, and contained false claims that Biden supports the far-left Antifa movement and backs sex change operations for children.Last week, Facebook saw a rocky start to its effort to ban new political messages a week ahead of the November 3 election.- Advertisement – – Advertisement –last_img read more

Read more →

Pink’s Daughter Shares ‘Wishes’ for Presidential Election

first_img– Advertisement – Putting in her two cents. Pink spoke to her 9-year-old daughter, Willow, about her “wishes” for the presidential election.“Well, my biggest wish is to go to Hogwarts,” the little one told the Grammy winner, 41, in a Tuesday, November 3, Instagram video, before noting that she wanted “peace” for the country.- Advertisement – Earlier that same day, the Pennsylvania native spoke about the importance of voting. “It is a right and responsibility that each citizen make their voice heard,” Pink captioned an Instagram photo of herself in a “VOTE” sweater. “Many have fought and died for the right to vote. I voted for Joe Biden and Kamala Harris. I will always use my voice.”As for her husband, Carey Hart, the former professional motocross competitor, 45, tweeted about his support for Biden, 77, earlier this month. “I’m a Republican who hates Trump, so I have no choice,” the California native wrote.- Advertisement – Willow also told the “Raise Your Glass” singer that she would like Joe Biden to beat Donald Trump. “Because he’s good,” she explained.Pink added, “No matter who wins the election that we can all figure out a way to be nicer to each other. That’s what I hope. Do you think that’s fair? Do you think that people should learn how to disagree and still be kind?” When Willow nodded, she said, “That’s what I wish.”Pink’s Daughter Willow Adorably Shares Her Wishes for the Presidential ElectionPink and Willow Sage Hart Rob Latour/ShutterstockJennifer Garner commented on the footage: “Thanks for this little bit of sweetness.”- Advertisement – The Inked author’s comments came just after he posted pictures of Willow and her brother, Jameson, 3, having a “fun morning shooting.” Hart wrote at the time: “Willz is getting seriously good with the rifle and handling of a firearm. And Jamo absolutely loves shooting! And the rate that he is processing the handling of them, he makes me proud. I’m a firm believer in teaching my kids to shoot, but more importantly, handle a firearm. No better sound than the bullet of your kids’ gun plucking a steel target at 30 yards.”When a Twitter user expressed confusion over his Democratic support when the party would “take” away guns, Hart denied that possibility, writing, “Why has none of the 44 [presidents] before been able to take them??”The off-road truck racer previously defended letting Willow shoot a rifle in January 2019. “Haven’t poked the parenting police bear in a few days,” Hart captioned an Instagram video at the time. “Willz and I shooting the 22 rifle. She is getting pretty good. Can hit a 12-inch pie plate from 30 yards. Started her shooting at 3yrs old. For the record non [sic] of us hunt, just enjoy shooting for sport. I’m raising the kids with knowledge of fire arms, how to handle them, shoot them, store them, and avoid them in uneducated hands. #knowledgeispower.”Listen to Us Weekly’s Hot Hollywood as each week the editors of Us break down the hottest entertainment news stories!last_img read more

Read more →

McConnell still fighting providing COVID-19 relief as hope dims for help before next year

first_imgTrump is going to wash his hands of this. It’s going to be up to McConnell, who is going to be more focused on jamming through all the judges he possibly can, and trying to figure out how to keep Georgia Democrats Jon Ossoff and Raphael Warnock out of the Senate. There is a Dec. 11 government funding deadline that could help drive some kind of added action on relief—maybe. “We want the Republicans to come back to the table,” Pelosi said. “The imperative to act could not be greater.” – Advertisement – “Our economy is really moving to get back on its feet. That I think clearly ought to affect what size of any rescue package we additionally do,” he said, speaking to reporters in Kentucky. “I do think we need another one, but I think it reinforces the argument that I’ve been making for the last few months that something smaller—rather than throwing another $3 trillion at this issue—is more appropriate, with it highly targeted towards things that are directly related to the coronavirus, which we all know is not going away until we get a vaccine.” That’s completely ignoring the resurgence of the virus all over the country and the prospects of an extremely grim winter.Asked if she would consider a smaller package, Pelosi was firm.”No, no, it doesn’t appeal to me at all because they still have not agreed to crush the virus,” Pelosi said. “That isn’t anything that we should even be looking at, it wasn’t the right thing to do before,” she added. With Trump now a lame duck, the only way anything happens from that side is if Treasury Secretary Steven Mnuchin continues to give a damn about the health of the economy and tries again. That would require a Donald Trump that was paying any attention to anything at all besides his grievances. Which is not likely.- Advertisement –last_img read more

Read more →

CDC: Resistance makes 2 older flu drugs ineffective

first_imgJan 14, 2006 (CIDRAP News) – The dominant strain of influenza virus in the United States has unexpectedly turned highly resistant to the two older antiviral flu drugs in use, prompting federal health officials today to advise physicians to stop using them for the rest of this season.The Centers for Disease Control and Prevention (CDC) announced that clinicians should stop prescribing amantadine and rimantadine, known as adamantanes, and substitute one of the two neuraminidase inhibitors—oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamivir and zanamivir are newer and more costly than amantadine and rimantadine, and many countries are stockpiling oseltamivir for possible use if the H5N1 avian flu virus evolves into a pandemic strain of flu.The CDC tested 120 influenza A(H3N2) virus isolates from around the nation and found that 109 of them, or 91%, were resistant to amantadine and rimantadine. That compares with 11% last year and only 1.9% the year before, the agency said.”What this means is that clinicians should not use amantadine or rimantadine to treat influenza because the drugs will not be effective,” CDC Director Dr. Julie Gerberding said at an unusual Saturday press teleconference today.”We don’t think this is going to affect a large number of patients, because not many patients typically are treated with these drugs,” Gerberding said.She explained that oseltamivir and zanamivir have increasingly been replacing amantadine and rimantadine, though she couldn’t give any figures. The newer drugs are effective against both A and B types of flu, whereas the older drugs work only for type A, and the newer drugs also may have fewer side effects, she said.Gerberding said the supply of oseltamivir for treating seasonal flu should be adequate even though the limited production capacity of Roche, the manufacturer, has hampered countries’ efforts to stockpile it in case of a pandemic.”We understand there’s a bottleneck of production that’s limiting our ability to build a stockpile, but . . . we’ve not experienced any shortages for treating patients,” she said. “The amount of Tamiflu in our stockpile far exceeds the amount of antivirals that have ever been used to treat influenza.”Gerberding said the CDC expects that oseltamivir and zanamivir will remain effective for treating flu “for the foreseeable future.” All H3 and H1 viruses tested have been susceptible to them, the agency said.Patients who are currently being treated with amantadine or rimantadine should be switched to one of the newer drugs immediately, she said.Using a new, high-throughput test for viral resistance, CDC scientists first noted the high frequency of resistance yesterday, Gerberding. But they wanted to confirm the findings further before making an announcement.”We just didn’t feel it was responsible to wait 3 more days to get through the [holiday] weekend,” she said in explaining the decision to announce the news today.”We don’t know what accounts for this unexpected increase in resistance,” Gerberding said. She said it could result from a spontaneous mutation or it could relate to overuse of amantadine and rimantadine in countries where the drugs don’t require a prescription.Resistance to the drugs has been increasing globally in recent years, she said, adding, “There is certainly a trend in the direction of increasing resistance, but I don’t think we were expecting it to be so dramatic so soon this year.”A CDC advisory for clinicians says that a single point mutation at any of five amino acid positions on the flu virus’s M2 protein can confer resistance to both amantadine and rimantadine. The mutation does not decrease the virus’s transmissibility.Gerberding said there is no evidence that the increased resistance makes H3N2 viruses more virulent.She stressed that the resistance finding pertains only to “good old, garden-variety seasonal flu” and is unrelated to avian flu or a potential flu pandemic.However, the CDC has been monitoring H5N1 avian flu viruses as they have become available, she said. “Some are susceptible to these drugs and some are resistant to these drugs,” she said. “I think the lesson here is that flu constantly evolves and you’re always one mutation away from increased resistance.”Countries have not stockpiled amantadine or rimantadine for use in a flu pandemic, because many of the H5N1 virus samples from Asia have been resistant to them. However, in recent months some H5N1 strains have been reported to be susceptible to the two drugs.Seasonal flu activity is beginning to increase around the country, with 18 states reporting either widespread or regional activity, the CDC said in a news release today.”This year over 80 million doses of vaccine have been distributed but remaining supplies vary from state to state so individuals may have to check with more than one provider to receive vaccine,” the agency said. “Also, CDC will have available 3.5 million doses from its stockpile to sell through manufacturers as soon as possible. In addition there are doses of vaccine presently available for sale by manufacturers and distributors.”See also:CDC information on antiviral drugs for influenzahttp://www.cdc.gov/flu/professionals/treatment/last_img read more

Read more →

System for global pandemic vaccine development challenged

first_imgFeb 6, 2007 (CIDRAP News) – Indonesia, the country that has seen more human deaths from avian influenza H5N1 than any other, has ceased sharing viruses isolated from its patients with international health authorities, challenging the global system for flu-strain identification and vaccine development.The World Health Organization (WHO) has not received any viral isolates from Indonesia since the end of 2006, Dr. David Heymann, the agency’s acting assistant director-general for communicable diseases, said in a telephone briefing this morning.”We have been in discussions with the Ministry of Health since November of last year,” he said. “We will continue to work with them and with all countries to ensure this virus will remain somehow a public good.”Indonesia is also preparing to sign on Wednesday an agreement giving a single vaccine manufacturer rights to its isolates, Heymann said—though by the end of the day Tuesday, it remained unclear whether the agreement with Baxter International would block health authorities and other manufacturers from accessing the samples, or solely guarantee Indonesia’s right to purchase vaccines made from its viruses.The episode highlights the fragile and increasingly contentious system by which flu viruses—from both seasonal flu and novel strains such as avian influenza H5N1—are identified and shared around the world.Under that system, designed by the WHO with the agreement of its 193 member states, flu viruses are isolated in a country and analyzed to increasing levels of sophistication by a national lab, regional lab, and 1 of 4 WHO Influenza Collaborating Centers in Tokyo, Melbourne, London, and the US Centers for Disease Control and Prevention in Atlanta.Gene sequences from the analyses are used to identify emerging strains of flu—to track the evolution of the disease and, crucially for Tuesday’s news, to provide the basis for flu vaccines made by pharmaceutical companies.For about 50 years, the system has operated on goodwill, with its costs borne by the WHO membership and no compensation offered for viral contributions. There have been signs in recent months, though, that the agreement is breaking down.China last year refused for a time to share flu virus samples internationally, complaining that credit for discoveries was going to Western scientists at the top of the network’s pyramid rather than to the Chinese researchers who originated them.And last month, developing-world members of the WHO’s 34-country Executive Board complained at the board’s annual meeting that the system routes viral isolates, and the vaccines that result from them, away from the developing countries that lack the capacity to manufacture them but are likely to need them the most.”The pandemic will definitely occur in developing countries, not developed countries. But we are sending our virus (samples) to the rich countries to produce antivirals and vaccines. And when pandemic occurs, they survive and we die,” Suwit Wibulpolprasert of Thailand said in remarks carried by Reuters.”We are not opposing the sharing of information and virus, but on the condition that every country will have equal opportunity to get access to vaccine and anti-virals if such a pandemic occurs.”He was supported by Sameer Khalfan of Bahrain, who said: “There should be a fixed percentage of the vaccine produced for the pandemic strain for each region, proportionate to the population of each region, to ensure equitable and fair access.”At the end of the meeting, the board passed a resolution—to be sent to the full membership for a vote during May’s World Health Assembly—that pointedly said: “No national influenza centre laboratory, Global Influenza Surveillance Collaborating Centre or H5 Reference Laboratory should charge fees or sell influenza viruses or strains or in any way seek to profit from participation in the WHO Global Influenza Surveillance Network. . . . No national, influenza centre laboratory, Global Influenza Surveillance Collaborating Centre or H5 Reference Laboratory should impose agreements or administrative procedures that may inhibit the proper functioning of the WHO Global Influenza Surveillance Network, including in particular the timely sharing of material and information.”Indonesia is a WHO member state but does not belong to the executive board.In the teleconference Tuesday, Heymann said the virus-sharing relationship has broken down over twin concerns of intellectual property rights and vaccine access.”Their major concern is that the virus strain they have put into the WHO network . . . has been used by several manufacturers to develop vaccines,” he said. “Indonesia feels they must be getting some compensation for the use of their viruses in production and marketing of these vaccines.”In addition to intellectual property rights, Heymann said, the dispute hinges on the mismatch between where vaccine seed strains originate and where the vaccines that result from them are sold. Most vaccine manufacturers are in the industrialized world, whose countries are also the major markets for seasonal vaccine. If a pandemic strain arises and a vaccine can be developed against it, developing countries that also want to purchase it could find themselves at the end of a long queue.”Developing countries . . . would like to have their own stockpiles, or would like to have some benefit from the viruses that they have given, seeing that there is not great access to vaccines in the world,” Heymann said.Indonesia is due Wednesday to sign a memorandum of understanding with vaccine manufacturer Baxter International. How much that memo could alter the relationship with the global flu-identification effort is unclear.”We anticipate the MOU will then modify the way in which Indonesia participates in the network for sharing of novel influenza viruses,” Heymann said. But Baxter told the Financial Times and Canadian Press today that the agreement would not block the sharing of Indonesian viral samples with others.Whatever the memo’s content, the issue of developing countries’ desire to exert some self-protective control over flu-virus identification is unlikely to go away—as Heymann acknowledged Tuesday.”The solution to this certainly comes from a round table at which many people are seated; that round table has to include pharmaceutical companies developing vaccines, it has to include countries that are having human infections, it has to have countries in whose interest it is to have those viruses and it has to have international organizations,” he said. “We have begun those discussions with the pharmaceutical industry, with the governments, and we are gradually trying to come to a paradigm that will work.”last_img read more

Read more →

EU approves its first prepandemic H5N1 vaccine

first_imgMay 19, 2008 (CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.The European Medicines Agency has approved the adjuvanted vaccine, called Prepandrix, for marketing in all 27 EU countries, GSK said in a news release. The vaccine offers European governments the opportunity to protect their populations “in advance or at the outset of a declared influenza pandemic,” the company said. The product is licensed for adults aged 18 to 60.The EU approval comes about 13 months after the US Food and Drug Administration approved the first H5N1 vaccine for the United States, made by Sanofi Pasteur.”This vaccine marks a significant step in the world’s ability to cope with an influenza pandemic,” GSK CEO Jean-Pierre Garnier said in the release.Disease experts hope that prepandemic vaccines, based on existing H5N1 strains, will offer some protection against an emerging pandemic strain of H5N1 until a specific pandemic vaccine can be developed and produced, a process expected to take 4 to 6 months.The EU approval is based on studies of a version of the vaccine involving an H5N1 strain isolated in Vietnam in 2004 (a clade 1 strain), the company said. Results of animal and human studies suggest that the vaccine may also offer protection against clade 2 strains of the virus.The vaccine contains an oil-and-water adjuvant that enables it to induce what is believed to be a protective immune response at low doses, according to published results. For example, two 3.8-microgram (mcg) doses generated immune responses that met all US and European criteria for vaccine licensing, according to findings published last August in The Lancet. By comparison, seasonal flu vaccines contain 15 mcg of antigen for each flu strain targeted.In addition, more than 75% of volunteers who received two 3.8-mcg doses of the vaccine were shown to have neutralizing antibodies against a clade 2 strain of H5N1, the Lancet report said.GSK announced last year it would donate 50 million doses of its H5N1 vaccine to the World Health Organization (WHO) to help launch an international prepandemic vaccine stockpile.The company said it has already sold supplies of its vaccine to the United States, Switzerland, and Finland. Officials said sales in 2007 totaled 146 million British pounds (US $284 million).The WHO said last week that at least 16 companies have H5N1 vaccines in advanced development.See also: May 19 GSK news releasehttp://www.gsk.com/media/press-releases/2008/first-pre-pandemic-vaccine-approved-to-help-protect-against-pandemic-influenza.htmlAug 27, 2007, CIDRAP News story “Trial results for Glaxo’s H5N1 vaccine released”Apr 17, 2007, CIDRAP News story “FDA approves first H5N1 vaccine”May 16 CIDRAP News story “Launch of WHO H5N1 vaccine stockpile still awaited”CIDRAP News seven-part article series “The pandemic vaccine puzzle”last_img read more

Read more →

FDA clears CSL’s vaccine-finishing facility in US

first_imgAug 18, 2009 (CIDRAP News) – The US Food and Drug Administration (FDA) today approved a vaccine filling and packaging facility in Illinois owned by CSL Biotherapies, one of the five companies under contract to make novel H1N1 vaccines for the United States, the company announced.The facility, based in Kanakee, includes a high-speed, single-dose vaccine filling line and is intended to help the company expand its capacity to make flu vaccine for the US market. The company, based in Australia, said in a press release that it completed production of its seasonal flu vaccine, Afluria, in early July and will deliver more than 8 million doses, most of it in thimerosal-free prefilled syringes, for the upcoming season.On May 29 CSL signed a $180 million contract with the US Department of Health and Human Services (HHS) to produce novel H1N1 antigen. Today’s FDA approval will enable the company to package the antigen, produced at the company’s headquarters in Australia, if requested by HHS. A company spokeswoman said in an e-mail sent to journalists today, “Today’s approval of this facility is particularly important as it will allow CSL to fill and package their vaccine against the novel influenza A/H1N1 virus in the US.”On Aug 14 during a National Biodefense Safety Board teleconference to update US officials on pandemic preparations, an HHS official scaled back the predicted initial supply of novel H1N1 vaccine from 120 million doses to 45 million doses by mid October, with 20 million doses arriving weekly thereafter. The official cited a US shortage of vaccine fill-and-finish sites, which are just finishing production of seasonal flu vaccines, as one of the reasons for the vaccine delay.Bill Hall, an HHS spokesman , told CIDRAP News today that the FDA’s approval of CSL’s new facility is clearly good news and is part of HHS’s strategy to maximize vaccine production and speed delivery. “However, it’s too early to predict at this point exactly how much this particular approval will enhance our overall production capacity and vaccine availability,” he added.Another reason cited for the reduced forecast regarding initial H1N1 vaccine supply was CSL’s contractual obligation to produce novel flu vaccine first for its home country, Australia, which is in the midst of its winter flu season. Officials also said one of the companies making seasonal flu vaccine is having problems finishing up production.When the Kanakee facility opens, it will have the capacity to fill and package 10 million doses of CSL’s seasonal flu vaccine each year, the company said. Once the site reaches full capacity it will be able to fill and package 20 million thimerosal-free prefilled syringes annually.Wally Casey, senior vice president and general manager of CSL’s Kanakee facility, said in a press release that the FDA’s approval today enables the company to rapidly deliver ready-to-administer flu vaccines to US healthcare providers. “It also underscores our support to enhance vaccine administration safety through the use of ready-to-use prefilled syringes,” he added.CSL said in a May 29 press release that it also has a fill-and-finish facility in Marburg, Germany.See also:Aug 18 CSL press releaseAug 14 CIDRAP News story “Officials lower expectations for size of first novel flu vaccine deliveries”May 29 CSL press releaselast_img read more

Read more →

Tourist offer of Riviera Crikvenica presented to travel agencies

first_imgThe 37th Assembly of the UHPA Professional Association and the 32nd Assembly of the UHPA Employers’ Association were held at the Westin Hotel in Zagreb. , enjoy, repeat ”and eno-gastronomic offer of Crikvenica.Apart from the film shown, the Riviera was also presented through a series of autochthonous dishes made by the famous chef Dragan Visković and the offer of the “Pavlomir” Winery. UHPA recognized the intensive development of new tourist products and exceptional results and growth of other tourist indicators of the destination and chose Crikvenica as the domestic destination of the year 2017/2018. which was just another reason to present the tourist offer to travel agencies.During the year, the Tourist Board of the City of Crikvenica, but also the entire Crikvenica Riviera, as a UHPA destination, receives a number of marketing and consulting activities, such as online destination promotion, promotion in UHPA publications (UHPA Directory and UHPA Professional Review), a separate brochure ( magazine “Way to Croatia” dedicated to the destination of the year) and in public appearances (for example, at workshops, assemblies and various events, the annual meeting “Days of UHPA”, etc.). In addition, representatives of the Crikvenica Riviera will have the opportunity to hold special presentations of the destination at various UHPA events. In addition to the two held, at the beginning of the year, two more educational workshops will be held for travel agencies in the Crikvenica Riviera, whose main goals will be to create new package deals and develop selective forms of tourism.Thanks to this project, Crikvenica will host the “UHPA Day 22” from March 24 to 2018, 2018, a multi-day annual meeting of travel agencies and other stakeholders in tourism. This largest gathering of travel agencies in Croatia with over 100 representatives of travel agencies and representatives of the Ministry of Tourism, the Croatian Chamber of Commerce and the Croatian Tourist Board is certainly an opportunity for additional promotion of the destination, but also strengthening cooperation with Croatian and foreign travel agencies.UHPA Assembly held The Assembly adopted the Financial Plan for the implementation of the work program of UHPA for 2018 and the election of members of the Management Board was held.Three new members are: Silvana Turčić, Obzor putovanja doo, Zagreb (representative of regular members from continental Croatia), Mile Uroda, Škver tours – Navale turizam jdoo, Biograd na Moru (representative of regular members from Northern Dalmatia) and Emina Marušić, Kompas Zagreb dd , Zagreb (representative of regular members with the largest number of point votes).Related news:CRIKVENICA GOT CITY BOAT – CITY SEA LINE CONNECTING ALL PLACESCRIKVENICA NAMED THE MOST SUCCESSFUL DESTINATION OF HEALTH TOURISMlast_img read more

Read more →

Large CCE survey: A third of respondents believe that the high season is at the same level as last year

first_imgThe vast majority of respondents (about 80 percent) are hotels, hostels, camps and private accommodation, according to the Croatian Chamber of Commerce, which conducted the survey. The majority of surveyed (58,5 percent) entrepreneurs did not adjust the prices of their services at all compared to last year. Nearly a quarter lowered prices before the start (12,7 percent) or during the high season (10,6 percent), while 18,3 percent of respondents raised prices in the same period. Although as many as three quarters of the respondents (74,3 percent) invested significantly in the quality of the offer during the preparations for this tourist season, these investments did not significantly affect prices. Tourist entrepreneurs who are satisfied with this season owe their success primarily to investments in the quality of the offer. This is also shown by the results of a survey conducted by the Croatian Chamber of Commerce among its members, in which the prevailing view is that the tourist season has not failed.  Sanela Vrkljan, Assistant Director of the Tourism Department of the Croatian Chamber of Commerce Cover photo: Medora Auri Family Beach Resort The key sales channels of respondents are direct sales (79,3 percent), travel agencies (46,4 percent) and online agencies (45,7 percent). Global distribution systems are the main sales channel for 30 percent of respondents, while 17,1 percent of them reach customers through fairs, B2B workshops and the like.center_img Thus, a third of respondents (32,6 percent) believe that the high season is at the same level as last year, and 33,3 percent believe that it is better than last year, or excellent (6,4 percent). A quarter of respondents (25,5 percent) rate the season as bad, and only 2,1 percent have the impression that it is extremely bad.  In addition to standard benefits, just over half of respondents (51,4 percent) also offer a wide range of additional content for guests. The offer includes everything from sports facilities and wellness to various excursions and tours through which guests get to know the local natural beauty, gastronomy and cultural tradition.  Price adjustments are mostly minimal. Over 40 percent of the subjects changed prices in the range of up to 5 percent compared to last season, and 30 percent made adjustments of 6 to 10 percent. Significant price changes of 11 to 20 percent were present in 13,2 percent of respondents, while 14,7 percent of them adjusted prices from 21 percent upwards.  “The results of the research clearly indicate that investments in the quality of the offer are the key to success in tourism. Modern tourists are better informed and more demanding, and all those who want full capacity and profitability must, following global trends, offer additional content designed according to the needs and desires of their guests. Each next season will be more and more challenging, so while maintaining price competitiveness, it is necessary to continuously invest and raise the quality of services and products in tourism.”Said Sanela Vrkljan, Assistant Director of the Tourism Department of the Croatian Chamber of Commerce. Investing in the quality of the offer is the key to success in tourism last_img read more

Read more →

Discussions about tourism @ EFZG: Private accommodation: Good, bad, evil?

first_imgScience and the profession often know how to emphasize that private accommodation is one of the competitive advantages of Croatian tourism. Private accommodation is an important distinguishing feature of Croatian tourism, which most Mediterranean competitors do not have, and at the same time ensures the existence of a significant part of the population. However, science and the profession can also emphasize that the uncontrolled growth of private accommodation can result in the degradation of space as the most important tourist resource, but also a number of other problems, thus jeopardizing the sustainability of the existing model of tourism and general economic development. The panelists who will participate in the discussion are Dr. sc. Vjekoslav Bratic, Director of the Institute of Public Finance, Martina Nimac Kalcina, President of the Family Tourism Association of the Croatian Chamber of Commerce, Ph.D. Damir Krešić, director of the Institute of Tourism, Sanja Šaban, Assistant Minister of Construction and Physical Planning, and Dr. sc. Maruška Vizek, director of the Institute of Economics. The discussions are jointly organized by the Department of Tourism of the Faculty of Economics – Zagreb and the Institute of Tourism, on the occasion of marking the 99th birthday of the Faculty. The panel discussion will be held at the Faculty of Economics, University of Zagreb, Hall 3, on Thursday, November 28, from 12:00 to 14:00. Private accommodation in Croatia has always had a wider social significance that goes beyond the usual economic understandings. Today, it is the most important segment of the accommodation offer in Croatian tourism with a share of over 60 percent in the total number of beds. The discussion will be moderated by Đuro Tomljenović, and is intended for the general and professional public, the media and anyone who wants to learn more about the issue of private accommodation. Recognizing different understandings, but also the need to differentiate between different forms of private accommodation in modern tourism practice, the aim of these discussions is to look at private accommodation from several important perspectives such as the relationship between private accommodation and real estate market in Croatia, the way private accommodation affects space and borders. its growth, the quality of the existing tax treatment and the reasonableness of treating all types of private accommodation in the same way and the importance of private accommodation for the Croatian economy and society as a whole. Admission is free, and arrival must be announced by e-mail: rasprave-turizam@net.efzg.hr.last_img read more

Read more →